Columns
- All
- Advanced Degrees
- Analyze This
- Back Page
- Clinically Speaking
- Data Integrity
- Deal Discussions
- Editorial
- Emerging Markets
- Executive Perspective
- FDA Watch
- Financial Analysis
- Getting Results
- I Mak
- India Report
- Lowe Down
- Managing Your Career
- Newsmakers Interviews
- Opinions & Best Practices
- PBOA News
- Pharma Beat
- Preclinical Outsourcing
- The BioPharm Insider
-
CMOs Growing Strong in APIs
Major API players in India continue to invest in operationsS Harachand, Contributing Editor 04.10.18
-
Innovate UK Grant Supports Viral Vector Manufacturing
Cobra Biologics talks about its recently awarded $3.4 million capital infrastructure investmentBetsy Louda, Associate Editor 04.10.18
-
New GXP Data Integrity Guidance Published by MHRA
New GXP Data Integrity Guidance Published by MHRARobert Marohn, ClinLogic, LLC 04.10.18
-
Some Changes in Formulation Paradigms
Old ways are slowly changing with the introduction of PAT and QbDEmil W. Ciurczak, DoraMaxx Consulting 04.10.18
-
How Does Work Get Done In Pharma? By PEOPLE!
A high-octane primer on talent development for better business performanceBen Locwin, Contributing Editor 04.10.18
-
Regulatory Affairs
Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle: ICH Q12
More than a decade after the birth of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) at a meeting in Brussels hosted by the European Federation of Pharmaceutical Industries and Associatio…Sharif Ahmed, Lachman Consultants 04.10.18
-
Leaving your Employer the ‘Right Way’
A look at the importance of finishing strong and going out on good termsRyan Raver and David G. Jensen, Contributing Editors 04.10.18
-
President Trump + Biologics = A Win for Drugmakers?
Are biosimilars the latest victim in the drug pricing war?Tim Wright, Editor 04.10.18
-
Packaging is Neither Simple Nor Un-important
Closing gaps on the packaging line will help avoid recallsEmil W. Ciurczak, DoraMaxx Consulting 03.12.18
-
Regulatory Affairs
Drug Safety Update
An uptick in adverse event reports doesn’t necessarily mean an increase in adverse eventsBen Locwin 03.12.18
-
Regulatory Affairs
OTC Drug Market Revenue to Exceed $178B by 2024
Growth driven by massive demand for health supplements and analgesicsGlobal Market Insights 03.09.18
-
Regulatory Affairs
From OMUFA To Opioids
CDMOs get involved in policyGil Roth, President, Pharma & Biopharma Outsourcing Association 03.09.18
-
Packaging Majors Expand Base in India
India’s pharma packaging market is growing at a faster pace than other world marketsS. Harachand, Contributing Editor 03.09.18
-
Healthcare Costs Run Rampant
Could Amazon, Berkshire Hathaway and J.P. Morgan Chase be the anti-ballistic missile needed to control and curb rising heaGirish Malhotra, Contributing Editor 03.09.18
-
Regulatory Affairs
FDA’s Increased Information Transparency
As a government entity, the U.S. Food and Drug Administration (FDA) has an obligation to provide transparency in its operations, which it does through its FDA Transparency Initiative.1 The goal is to enhance the understanding of stakeholders in FDA&r…Ricki A. Chase, Lachman Consultants 03.09.18
-
Keep the Home Fires Burning
Work/life balance is a topic more and more companies are addressing.David G. Jensen, Contributing Editor 03.09.18
-
Analyzing Developments in the CAR-T Field
A detailed look at opportunities and limitations of current T-cell therapiesDr. John Savin, Edison Invesment Reseach Ltd. 01.30.18
-
Acquisition Spree
Indian firms topped the list of aggressive bidders even as the frenzy of deal making in the global generics space passes intoS. Harachand, Contributing Editor 01.30.18
-
When Your Product is Neither a Liquid or a Solid
And you need to analyze/control it, in real timeEmil W. Ciurczak, DoraMaxx Consulting 01.30.18
-
Considering a Career Move?
Here are some key questions to ponder if you’re thinking about changing jobs.David G. Jensen, Contributing Editor 01.30.18
